Transplantation of mesenchymal stem cells in multiple sclerosis

To assess safety and tolerability of treatment with autologic multipotent mesenchymal stem cells (MSC) in multiple sclerosis (MS), we have obtained autologic red bone marrow-derived MSC from 8 patients. Proliferation, immunophenotype and caryotype of MSC, their sterility, the absence of hemopoetic c...

Full description

Saved in:
Bibliographic Details
Published inZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Vol. 111; no. 2 Pt 2; p. 72
Main Authors Odinak, M M, Bisaga, G N, Novitskiĭ, A V, Tyrenko, V V, Fominykh, M S, Bilibina, A A, Krugliakov, P V, Polyntsev, D G
Format Journal Article
LanguageRussian
Published Russia (Federation) 2011
Subjects
Adult
Humans
Infusions, Intravenous
Male
Mesenchymal Stem Cell Transplantation
Middle Aged
Multiple Sclerosis - physiopathology
Multiple Sclerosis - surgery
Transplantation, Autologous
Treatment Outcome
Young Adult
Online AccessGet more information

Cover

More Information
Summary:To assess safety and tolerability of treatment with autologic multipotent mesenchymal stem cells (MSC) in multiple sclerosis (MS), we have obtained autologic red bone marrow-derived MSC from 8 patients. Proliferation, immunophenotype and caryotype of MSC, their sterility, the absence of hemopoetic cells, chromosomal aberrations and signs of aging were controlled during the cell growth. The inverse injection of MSC in patient's blood was conducted in accordance to the elaborated protocol in a short intravenous infusion in dose 2.0 x 10(6)/kg of body mass once in 30 days. The duration of treatment was from 4 to 8 months. The efficacy of treatment was assessed after 4, 8 and 12 months. All patients tolerated repeated intravenous infusions of autologic MSC well with no significant side-effects as in the early as well in the remote periods of treatment. The distinct positive effect was seen in some cases 2 months after the beginning of treatment. The improvement of 0.5 point on EDSS was seen in 5/8 patients after 4 months. After 12 months, the improvement of 0.5-1 point on EDSS was seen in 6/8, stabilization in 1/8, progression in 1/8. These results revealed the safety of the elaborated protocol of treatment and the moderate clinical efficacy of treatment in non-curable patients or those with poor response to treatment that suggested continuing the study and enrollment of new patients.
ISSN:1997-7298